Author:
Matsubara Kousaku,Takahashi Yoshiyuki,Hayakawa Akira,Tanaka Fumiko,Nakadate Hisaya,Sakai Michio,Maeda Naoko,Oka Toshiaki,Ishii Eiichi,Bessho Fumio,Morimoto Tsuyoshi,Goto Hiroaki,Hashii Yoshiko,Hatakeyama Naoki,Shirahata Akira,Imaizumi Masue
Publisher
Springer Science and Business Media LLC
Reference24 articles.
1. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA, American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117:4190–207.
2. Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013;98:24–33.
3. Giulino LB, Bussel JB, Neufeld EJ; Pediatric and Platelet Immunology Committees of the TMH Clinical Trial Network. Treatment with rituximab in benign and malignant hematologic disorders in children. J Pediatr. 2007;150:338–44, 344.e1.
4. Arnold DM, Dentali F, Crowther MA, Meyer RM, Cook RJ, Sigouin C, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146:25–33.
5. Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146:217–21.
Cited by
17 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献